OptimizeRX (OPRX) Reiterated at Market Outperform by Citizens Amid Upsell Opportunity

June 29, 2026 4:44 AM

Citizens analyst Constantine Davides reiterated a Market Outperform rating and $9.00 price target on OptimizeRX (NASDAQ: OPRX).The analyst commented, "Management ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found